-
公开(公告)号：US20100184823A1
公开(公告)日：2010-07-22
申请号：US12667631
申请日：2008-07-04
IPC分类号： A61K31/7088 , C07H21/02 , C12N5/10 , A61K9/127 , C12N5/02
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propagation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽 （PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞之间的正链RNA病毒繁殖的方法。
-
公开(公告)号：US08603995B2
公开(公告)日：2013-12-10
申请号：US13359129
申请日：2012-01-26
IPC分类号： C12N15/113 , C07H21/04
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
-
公开(公告)号：US20120129913A1
公开(公告)日：2012-05-24
申请号：US13359129
申请日：2012-01-26
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽 （PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞内的正链RNA病毒传播的方法。
-
公开(公告)号：US20100183613A1
公开(公告)日：2010-07-22
申请号：US12582242
申请日：2009-10-20
IPC分类号： A61K39/395 , A61K31/713 , A61K38/02 , A61K31/357 , A61K31/7088 , A61P31/14
CPC分类号： C12N9/88 , C12N15/1137 , C12N2310/14 , C12Y401/01033
摘要： The present invention provides novel methods of reducing Flavivirus viral replication and/or infection, e.g., Dengue virus. The invention employs mevalonate decarboxylase (MVD) antagonists to inhibit the cholesterol biosynthesis pathway, thereby inhibiting viral replication/infection.
摘要翻译： 本发明提供了减少黄病毒病毒复制和/或感染的新方法，例如登革热病毒。 本发明使用甲羟戊酸脱羧酶（MVD）拮抗剂抑制胆固醇生物合成途径，从而抑制病毒复制/感染。
-
公开(公告)号：US20140057965A1
公开(公告)日：2014-02-27
申请号：US14069642
申请日：2013-11-01
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1137 , A61K31/713 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3233 , C12N2310/3515 , C12N2310/531 , Y02A50/385 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression of phosphatidylinositol 4-kinase (PI4K), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (PIK4CB) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (PIK4CA), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PIK4CB or PIK4CA target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propogation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向磷脂酰肌醇4-激酶（PI4K）的基因表达的双链核糖核酸（dsRNA），特别是人磷脂酰肌醇4-激酶，催化的β多肽（PIK4CB）或人磷脂酰肌醇4-激酶，催化的α多肽 （PIK4CA），以及它们用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分PIK4CB或PIK4CA靶mRNA基本上互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞内的正链RNA病毒传播的方法。
-
公开(公告)号：US20100183704A1
公开(公告)日：2010-07-22
申请号：US12562349
申请日：2009-09-18
IPC分类号： A61K9/127 , C12N5/00 , C12N5/02 , C12N15/63 , A61P31/14 , A61K31/7088 , C07H21/02 , A61P31/20
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
摘要： The invention relates to double-stranded ribonucleic acids (dsRNAs) targeting gene expression carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), and their use for treating infection by positive stranded RNA viruses such as hepatitis C virus (HCV). Each dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the CAD target mRNA. A plurality of such dsRNA may be employed to provide therapeutic benefit. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, and including a delivery modality such as fully encapsulated liposomes or lipid complexes. The invention further includes methods for treating diseases caused by positive stranded RNA virus infection using the pharmaceutical compositions; and methods for inhibiting the propagation of positive stranded RNA viruses in and between cells.
摘要翻译： 本发明涉及靶向基因表达氨基甲酰磷酸合成酶2，天冬氨酸转氨甲酰酶和二氢激酶（CAD）的双链核糖核酸（dsRNA）及其用于治疗由正链RNA病毒如丙型肝炎病毒（HCV）感染的用途。 每个dsRNA包含具有长度小于30个核苷酸的核苷酸序列的反义链，其长度通常为19-25个核苷酸，并且其与至少一部分CAD靶mRNA基本互补。 可以使用多种这样的dsRNA来提供治疗益处。 本发明还涉及包含dsRNA与药学上可接受的载体的药物组合物，并且包括递送方式如完全包封的脂质体或脂质复合物。 本发明还包括使用药物组合物治疗由正链RNA病毒感染引起的疾病的方法; 以及用于抑制细胞内和细胞之间的正链RNA病毒繁殖的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.021 秒)
